Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company, will be participating in the Bank of America Securities Health Care Conference and H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company, will be participating in the Bank of America Securities Health Care Conference and H.C. Wainwright 2nd Annual BioConnect Investor Conference. The company's management will give presentations at these events, showcasing their work in immuno-neurology. Webcasts of the presentations will be available on the Alector website.
Details
News Market Reaction – ALEC
The recorded move for ALEC in the trading session of this news was +0.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
- Bank of America Securities Health Care Conference (Las Vegas, Nevada)
- Tuesday, May 14, 2024, at 8:55 a.m. PT, corporate presentation
- H.C. Wainwright 2nd Annual BioConnect Investor Conference (New York, New York)
- Monday, May 20, 2024, at 11:00 a.m. ET, fireside chat
A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.